Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1201-1210 of 1,281) with videos related to

Pageof 129
Sort By:
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
The Oncologist|April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.
British Journal of Cancer|November 21, 2024
Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology researchSamir H Barghout, Nicholas Meti, Simren Chotai, et al.
Cancers|July 9, 2022
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) ComponentsRama Soundararajan, Paul Viscuse, Patrick Pilie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch, George R Blumenschein, Jeffrey A Engelman, et al.
The European Respiratory Journal|January 24, 2015
Plasma pro-surfactant protein B and lung function decline in smokersJanice M Leung, John Mayo, Wan Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung AdenocarcinomaErin L Stewart, Celine Mascaux, Nhu-An Pham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung CancerLinda Kachuri, Jens Helby, Stig Egil Bojesen, et al.
Pageof 129

Showing results (1201-1210 of 1,281) with videos related to

Sort By:
Pageof 129
Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.
The Oncologist|April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.
British Journal of Cancer|November 21, 2024
Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology researchSamir H Barghout, Nicholas Meti, Simren Chotai, et al.
Cancers|July 9, 2022
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) ComponentsRama Soundararajan, Paul Viscuse, Patrick Pilie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch, George R Blumenschein, Jeffrey A Engelman, et al.
The European Respiratory Journal|January 24, 2015
Plasma pro-surfactant protein B and lung function decline in smokersJanice M Leung, John Mayo, Wan Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung AdenocarcinomaErin L Stewart, Celine Mascaux, Nhu-An Pham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung CancerLinda Kachuri, Jens Helby, Stig Egil Bojesen, et al.
Pageof 129